Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Niraparib for the Treatment of Recurrent High Grade Glioma

Trial Status: administratively complete

This phase II trial tests the safety and side effects of niraparib and whether it works to shrink tumors in patients with high grade brain tumor (glioma) that has come back (recurrent). Niraparib is a PARP inhibitor. PARP is a protein that helps repair damaged DNA. Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.